Htgm

theantares

Nuovo Utente
Registrato
23/10/20
Messaggi
1.332
Punti reazioni
46
Pare che Pfizer la tecnologia HTGM la utilizzi

DA899CDB-6AF1-4EBF-8B8F-D5CF1563C27B.png
 

The Miracle

The game never ends
Registrato
17/9/00
Messaggi
13.215
Punti reazioni
627
Uscito ad 85c.. un po' troppo presto, ora è 1$.
Solita vecchia regola: se guadagno non mi lagno. ( A patto che non siano briciole ).
 

theantares

Nuovo Utente
Registrato
23/10/20
Messaggi
1.332
Punti reazioni
46
Ahhhhhh, mamma mia che occasione questa. La collaborazione con Pfizer sarebbe stato un bel campanello per andare long a lungo.
Peccato non abbiano rilasciato molte info sulla presentazione fatta, la schermata che avevo postato l'ho trovata per vie traverse chiedendo un approfondimento su un commento su Stockwits e per fortuna quella buon'anima a cui ho chiesto info ha deciso di postarla, altrimenti si faticava a trovare riscontri.
 

theantares

Nuovo Utente
Registrato
23/10/20
Messaggi
1.332
Punti reazioni
46
Oggi sono rientrato, in after c’è un bel movimento
 

theantares

Nuovo Utente
Registrato
23/10/20
Messaggi
1.332
Punti reazioni
46
TUCSON, Ariz., Sept. 20, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that the Fundación Instituto Valenciano de Oncología, located in Valencia, Spain (IVO), with its partners, the Fundación Pública Andaluza Progreso y Salud (FPS) and the Centro de Investigación Biomédica en Red (CIBER), have developed a laboratory-developed test (LDT) (the MPD Test) for the assessment of breast cancer recurrence based on their use of the HTG EdgeSeq™ technology.


This innovative test for patients with HR+/HER2- early-stage breast cancer was developed by IVO and its partners to identify patients with an increased risk of developing distant metastasis or relapse who may benefit from adjuvant chemotherapy. IVO is among the top 50 cancer hospitals in the world; FPS is a public entity mainly dedicated to research and information technology; and CIBER is a public research consortium devoted to advancing research in biomedicine and health sciences.

This highly qualified and experienced team of researchers has partnered to develop and validate the MPD Test using the HTG EdgeSeq technology, which typically requires only one single 5 μm-thin FFPE tissue biopsy section, coupled with the sensitivity and dynamic range of next-generation sequencing (NGS)-based detection, to generate results in as little as 3 days.

"We are thrilled that three of Spain's most renowned cancer research organizations have chosen to leverage HTG's innovative technology to improve precision medicine for breast cancer patients," said Byron Lawson, Senior Vice President and Chief Commercial Officer of HTG. "The MPD Test is a great example of how the HTG EdgeSeq technology can be used not only for molecular profiling and analysis, but also as a predictive tool for advancing precision medicine."

"Among the challenges of traditional genomic testing in early-stage HR+/HER2- breast cancer is the wide variation in risk assessment," said Dr. José Antonio López-Guerrero, Head of Molecular Biology Laboratory at IVO. "Discordant results between two different genomic assays can have a significant clinical impact on patients, determining, for example, whether or not a patient chooses to undergo chemotherapy. Leveraging HTG's EdgeSeq technology, we believe that the MPD Test represents a cost-effective option to shorten the time to result, reduce the risk of potential bias and improve the overall risk profile using only a small sample from a tissue biopsy."

The MPD Test is available as an LDT provided by IVO and its partners.
 

Salva_Tori

Nuovo Utente
Registrato
12/6/07
Messaggi
10.436
Punti reazioni
245
TUCSON, Ariz., Sept. 20, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that the Fundación Instituto Valenciano de Oncología, located in Valencia, Spain (IVO), with its partners, the Fundación Pública Andaluza Progreso y Salud (FPS) and the Centro de Investigación Biomédica en Red (CIBER), have developed a laboratory-developed test (LDT) (the MPD Test) for the assessment of breast cancer recurrence based on their use of the HTG EdgeSeq™ technology.


This innovative test for patients with HR+/HER2- early-stage breast cancer was developed by IVO and its partners to identify patients with an increased risk of developing distant metastasis or relapse who may benefit from adjuvant chemotherapy. IVO is among the top 50 cancer hospitals in the world; FPS is a public entity mainly dedicated to research and information technology; and CIBER is a public research consortium devoted to advancing research in biomedicine and health sciences.

This highly qualified and experienced team of researchers has partnered to develop and validate the MPD Test using the HTG EdgeSeq technology, which typically requires only one single 5 μm-thin FFPE tissue biopsy section, coupled with the sensitivity and dynamic range of next-generation sequencing (NGS)-based detection, to generate results in as little as 3 days.

"We are thrilled that three of Spain's most renowned cancer research organizations have chosen to leverage HTG's innovative technology to improve precision medicine for breast cancer patients," said Byron Lawson, Senior Vice President and Chief Commercial Officer of HTG. "The MPD Test is a great example of how the HTG EdgeSeq technology can be used not only for molecular profiling and analysis, but also as a predictive tool for advancing precision medicine."

"Among the challenges of traditional genomic testing in early-stage HR+/HER2- breast cancer is the wide variation in risk assessment," said Dr. José Antonio López-Guerrero, Head of Molecular Biology Laboratory at IVO. "Discordant results between two different genomic assays can have a significant clinical impact on patients, determining, for example, whether or not a patient chooses to undergo chemotherapy. Leveraging HTG's EdgeSeq technology, we believe that the MPD Test represents a cost-effective option to shorten the time to result, reduce the risk of potential bias and improve the overall risk profile using only a small sample from a tissue biopsy."

The MPD Test is available as an LDT provided by IVO and its partners.

notizie positive ma il titolo reagisce all' opposto :confused:
 

theantares

Nuovo Utente
Registrato
23/10/20
Messaggi
1.332
Punti reazioni
46
Intanto vediamo oggi, l'after di ieri era piuttosto farlocco visti i volumi pressoché nulli.
 

paperonzo

Nuovo Utente
Registrato
5/10/19
Messaggi
37
Punti reazioni
0
Salve a tutti vi chiedo scusa se irrompo come un”asteroide” potete dirmi qualcosa su Precision Biosciences (DTIL)?
 

theantares

Nuovo Utente
Registrato
23/10/20
Messaggi
1.332
Punti reazioni
46
On November 18, 2022, HTG Molecular Diagnostics, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that, as a result of the Company’s stockholders’ equity falling below $2.5 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company does not satisfy one of The Nasdaq Capital Market continued listing requirement set forth in Nasdaq Stock Market Rule 5550(b) (the “Rule”).
Pursuant to the Notice and Nasdaq rules, the Company has 45 calendar days, or until January 2, 2023, to submit a plan to regain compliance with the Rule. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice for the Company to provide evidence of compliance. There can be no assurance that the Company will be able to regain compliance with the Rule.